A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
About this item
Full title
Author / Creator
Publisher
Cairo, Egypt: Hindawi Limiteds
Journal title
Language
English
Formats
Publication information
Publisher
Cairo, Egypt: Hindawi Limiteds
Subjects
More information
Scope and Contents
Contents
Objectives. Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted therapy, also was assessed in a single-arm trial (ERIVANCE). We examined the comparative effectiveness of the two d...
Alternative Titles
Full title
A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_913f225d67ed4cf7be85f833e48ead12
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_913f225d67ed4cf7be85f833e48ead12
Other Identifiers
ISSN
2090-2905
E-ISSN
2090-2913
DOI
10.1155/2017/6121760
